LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 57.01% | 102.29% | 106.35% | 50.68% | -7.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.01% | 102.29% | 106.35% | 50.68% | -7.53% |
| Cost of Revenue | 35.37% | 94.22% | 84.90% | -4.99% | -25.07% |
| Gross Profit | 151.99% | 117.92% | 197.10% | 108.02% | 3,574.00% |
| SG&A Expenses | 54.04% | 32.41% | -64.75% | -91.01% | -36.75% |
| Depreciation & Amortization | 4.47% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.63% | 58.55% | -9.64% | -24.52% | -28.66% |
| Operating Income | 133.58% | 78.51% | 107.49% | 105.78% | 78.22% |
| Income Before Tax | 50.18% | 51.15% | 94.80% | 84.26% | 49.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.18% | 51.15% | 94.80% | 84.26% | 49.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.18% | 51.15% | 94.80% | 84.26% | 49.48% |
| EBIT | 133.58% | 78.51% | 107.49% | 105.78% | 78.22% |
| EBITDA | 355.65% | 155.63% | 123.94% | 106.81% | 110.54% |
| EPS Basic | 63.77% | 61.70% | 95.61% | 86.41% | 60.34% |
| Normalized Basic EPS | 57.89% | 59.32% | 92.02% | 86.14% | 65.14% |
| EPS Diluted | 66.67% | 61.70% | 95.61% | 86.41% | 56.90% |
| Normalized Diluted EPS | 57.89% | 59.32% | 92.02% | 86.14% | 65.14% |
| Average Basic Shares Outstanding | 39.60% | 28.31% | 20.78% | 14.74% | 27.51% |
| Average Diluted Shares Outstanding | 39.84% | 28.46% | 20.78% | 14.74% | 27.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
